De Boer AG - Search Results

1

The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone.

Karssen AM, Meijer OC, van der Sandt IC, De Boer AG, De Lange EC, De Kloet ER. Karssen AM, et al. Among authors: de lange ec, de kloet er, de boer ag. J Endocrinol. 2002 Oct;175(1):251-60. doi: 10.1677/joe.0.1750251. J Endocrinol. 2002. PMID: 12379510

2

Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice.

Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Meijer OC, et al. Among authors: de lange ec, de kloet er, de boer ag. Endocrinology. 1998 Apr;139(4):1789-93. doi: 10.1210/endo.139.4.5917. Endocrinology. 1998. PMID: 9528963

3

In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.

de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, Couet W. de Lange EC, et al. Among authors: de boer ag. Eur J Pharm Sci. 2000 Dec;12(2):85-93. doi: 10.1016/s0928-0987(00)00149-4. Eur J Pharm Sci. 2000. PMID: 11102735

4

Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier.

Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. Gaillard PJ, et al. Among authors: de boer ag. Pharm Res. 2000 Oct;17(10):1198-205. doi: 10.1023/a:1026406528530. Pharm Res. 2000. PMID: 11145224

5

Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain.

Karssen AM, Meijer OC, van der Sandt IC, Lucassen PJ, de Lange EC, de Boer AG, de Kloet ER. Karssen AM, et al. Among authors: de lange ec, de kloet er, de boer ag. Endocrinology. 2001 Jun;142(6):2686-94. doi: 10.1210/endo.142.6.8213. Endocrinology. 2001. PMID: 11356720

6

Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.

van der Sandt IC, Smolders R, Nabulsi L, Zuideveld KP, de Boer AG, Breimer DD. van der Sandt IC, et al. Among authors: de boer ag. Eur J Pharm Sci. 2001 Aug;14(1):81-6. doi: 10.1016/s0928-0987(01)00150-6. Eur J Pharm Sci. 2001. PMID: 11457654

7

P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier.

van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD. van der Sandt IC, et al. Among authors: de boer ag. Pharm Res. 2001 May;18(5):587-92. doi: 10.1023/a:1011016923346. Pharm Res. 2001. PMID: 11465412

8

The role of drug transporters at the blood-brain barrier.

de Boer AG, van der Sandt IC, Gaillard PJ. de Boer AG, et al. Annu Rev Pharmacol Toxicol. 2003;43:629-56. doi: 10.1146/annurev.pharmtox.43.100901.140204. Epub 2002 Jan 10. Annu Rev Pharmacol Toxicol. 2003. PMID: 12415123 Review.

9

Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.

van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD. van der Sandt IC, et al. Among authors: de boer ag. Eur J Pharm Sci. 2000 Sep;11(3):207-14. doi: 10.1016/s0928-0987(00)00097-x. Eur J Pharm Sci. 2000. PMID: 11042226

10

BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123.

de Lange EC, de Bock G, Schinkel AH, de Boer AG, Breimer DD. de Lange EC, et al. Among authors: de bock g, de boer ag. Pharm Res. 1998 Nov;15(11):1657-65. doi: 10.1023/a:1011988024295. Pharm Res. 1998. PMID: 9833984

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

301 results

Search Page

Filters